5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis.

摘要: Objectives To switch patients with ulcerative colitis (UC) from costlier 5-aminosalicylic acid compounds to sulfasalazine and assess (1) the cost savings, (2) barriers switching, (3) adverse events (AEs) adherence at 3 months after drug switch. Study design An open-label, pharmacist-administered program coordinated an academic inflammatory bowel disease center. Methods A clinical pharmacist contacted UC who were prescreened by physicians covered specific insurers enroll them in program. Enrolled followed for AEs medication adherence. Reasons declining participate recorded. Results total of 205 eligible identified; only 14 enrolled, 10 remained on entire 3-month follow-up period. The enrollment rate was 4.9%, yet a net savings $22,828/3-month insurer achieved (including administration costs but excluding AE costs), co-pays reduced approximately $25 per month patient. (28.6%) similar that found previous reports. Significant unanticipated switching encountered, namely patient desire not alter existing effective regimen. Conclusions significantly more difficult than anticipated, questionable achievement savings. This experience suggests future switches studies should focus preferences as this may have implications brand name biosimilar drugs.